Pregabalin市場規模、佔有率和成長分析（按劑型、應用、藥物類別、通路、最終用戶和地區分類）—2026-2033年產業預測

預計到 2024 年，全球Pregabalin市場規模將達到 19.7 億美元，到 2025 年將達到 20.5 億美元，到 2033 年將達到 27.6 億美元，預測期（2026-2033 年）的複合年成長率為 3.8%。

受神經系統疾病（尤其是癲癇和神經病變疼痛）在成人中日益普遍的影響，Pregabalin市場正經歷顯著成長。市場相關人員致力於改善低收入和醫療服務不足地區的用藥可及性，也促進了這一成長。全球有超過5000萬人患有癲癇，由於許多患者預計將透過適當的治療實現無癲癇發作，因此對Pregabalin的需求仍然強勁。成人，尤其是25至60歲的人群，是該市場的主要消費群體，他們患有神經病變疼痛、纖維肌痛和整體焦慮症等慢性疾病的比例最高。此外，低收入國家治療資源的匱乏凸顯了提高藥物可及性的必要性，進一步推動了Pregabalin市場的成長。

全球Pregabalin市場促進因素

神經病變疼痛和整體焦慮症發病率的不斷上升顯著推動了全球對Pregabalin的需求。已開發國家和發展中國家的醫療專業人員擴大推薦Pregabalin，因為它具有治療慢性疼痛和緩解焦慮症狀的雙重療效。此外，世界各地更新的臨床指南已將Pregabalin列為一線治療藥物，擴大了其在神經病學和精神病學領域的應用。Pregabalin日益成長的認可度和適應症範圍，使其在旨在改善患者預後的藥物治療中扮演越來越重要的角色。

限制全球Pregabalin市場的因素

由於Pregabalin在許多地區被列為管制藥物，其全球市場面臨許多挑戰，限制了市場成長。對濫用和成癮風險的擔憂促使監管機構實施了嚴格的處方限制。這些限制阻礙了Pregabalin的普及，尤其是在全科診所和門診機構，因為醫療服務提供者可能由於繁瑣的文書工作而猶豫是否開立處方。此外，全面的記錄和監測要求也可能進一步阻礙一些醫療專業人員向患者提供該藥物，從而阻礙整體市場滲透，並限制了可能受益於該治療的患者獲得治療的機會。

全球Pregabalin市場趨勢

全球Pregabalin市場正處於顯著成長階段，這主要得益於市場對有效神經病變疼痛緩解方案日益成長的需求。隨著慢性疼痛在老年族群中持續增加，尤其是在北美和歐洲，醫療保健提供者和患者都擴大選擇Pregabalin來治療糖尿病神經病變和帶狀皰疹後遺症神經痛等疾病。這種需求的激增促使製藥公司致力於推出特殊劑型和長效製劑，以滿足不同患者的需求。尤其關注老年患者群體，凸顯了製藥業在提高疼痛管理策略的耐受性和依從性方面所做的努力。

目錄

介紹

• 調查目標
• 調查範圍
• 定義

調查方法

• 資訊收集
• 二手資料和一手資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分市場機會分析

市場動態與展望

• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制與挑戰
• 波特分析

關鍵市場考察

• 關鍵成功因素
• 競爭程度
• 關鍵投資機會
• 市場生態系統
• 市場吸引力指數（2025）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析
• 案例研究
• 顧客購買行為分析

全球Pregabalin市場規模（依劑型分類）及複合年成長率（2026-2033 年）

• 口服膠囊
• 口服液
• 口服錠劑
• 緩釋製劑

全球Pregabalin市場規模（依應用及複合年成長率分類）（2026-2033 年）

• 癲癇
• 神經病變疼痛
• 焦慮症
• 其他

全球Pregabalin市場規模（依藥物類別及複合年成長率分類）（2026-2033 年）

• 纖維肌痛治療藥物
• 抗驚厥藥
• 其他

全球Pregabalin市場規模（依通路分類）及複合年成長率（2026-2033 年）

• 醫院藥房
• 零售藥房
• 網路藥房
• 其他

全球Pregabalin市場規模（依最終用戶分類）及複合年成長率（2026-2033 年）

• 醫院
• 專科診所
• 居家醫療
• 其他

全球Pregabalin市場規模及複合年成長率（2026-2033）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 亞太其他地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業的市場定位（2025 年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市佔率分析（2025 年）
• 主要企業公司簡介
  • 公司詳情
  • 產品系列分析
  • 依業務板塊進行公司股票分析
  • 2023-2025年營收年比比較

主要企業簡介

• Pfizer Inc.（US）
• GSK plc（UK）
• Novartis AG（Switzerland）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Sanofi（France）
• F. Hoffmann-La Roche Ltd.（Switzerland）
• Zydus Cadila（India）
• Lupin（India）
• Amneal Pharmaceuticals LLC.（US）
• Cipla Inc.（US）
• Torrent Pharmaceuticals Ltd.（India）
• Aurobindo Pharma Limited（India）
• Glenmark Pharmaceuticals Limited（India）
• Medley Pharmaceuticals Ltd.（India）
• Genesisbiotec（India）
• Biomax Biotechnics（India）

結論與建議

Global Pregabalin Market size was valued at USD 1.97 Billion in 2024 and is poised to grow from USD 2.05 Billion in 2025 to USD 2.76 Billion by 2033, growing at a CAGR of 3.8% during the forecast period (2026-2033).

The pregabalin market is experiencing significant growth driven by the increasing prevalence of neurological disorders, particularly epilepsy and neuropathic pain among adults. Efforts by market players to enhance access in low-income and underserved regions are also contributing to this expansion. With over 50 million individuals worldwide affected by epilepsy, and a large percentage potentially achieving seizure freedom through proper treatment, the demand for pregabalin remains robust. The adult demographic, particularly those aged 25 to 60, displays the highest incidence of chronic conditions such as neuropathic pain, fibromyalgia, and generalized anxiety disorder, making it the primary consumer segment. Furthermore, significant gaps in treatment availability in low-income countries highlight the need for improved accessibility, thereby further propelling the growth of the pregabalin market.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Pregabalin market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Pregabalin Market Segments Analysis

Global Pregabalin Market is segmented by Forms, Application, Drug Class, Distribution Channel, End User and region. Based on Forms, the market is segmented into Oral Capsule, Oral Solution, Oral Tablet and Extended Release. Based on Application, the market is segmented into Epilepsy, Neuropathic Pain, Anxiety Disorder and Others. Based on Drug Class, the market is segmented into Fibromyalgia Agents, Anticonvulsants and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Others. Based on End User, the market is segmented into Hospitals, Specialty Clinics, Homecare and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Pregabalin Market

The growing incidence of neuropathic pain and generalized anxiety disorders is significantly boosting the global demand for pregabalin. Healthcare professionals in both advanced and developing regions are increasingly recommending pregabalin due to its dual therapeutic applications in managing chronic pain and alleviating anxiety symptoms. Furthermore, the inclusion of pregabalin as a first-line treatment option in updated clinical guidelines across various countries is enhancing its utilization in the fields of neurology and psychiatry. This expanding acceptance and application of pregabalin are contributing to its rising prominence in pharmaceutical therapies aimed at improving patient outcomes.

Restraints in the Global Pregabalin Market

The global pregabalin market faces significant challenges due to its classification as a controlled substance in many regions, which restricts its market growth. Concerns over potential abuse and dependency prompt regulatory bodies to enforce stringent prescribing restrictions. These regulations create barriers for adoption, particularly among general care units and outpatient settings, as healthcare providers may hesitate to prescribe pregabalin due to the increased administrative requirements involved. The need for comprehensive record keeping and oversight may further discourage some practitioners from offering it to patients, ultimately hindering its overall penetration in the market and limiting accessibility for those who may benefit from the treatment.

Market Trends of the Global Pregabalin Market

The global pregabalin market is witnessing a notable upward trajectory, driven by heightened demand for effective neuropathic pain relief solutions. As chronic pain disorders, particularly prevalent among the aging population in North America and Europe, continue to rise, healthcare providers and patients alike are increasingly turning to pregabalin for managing conditions like diabetic neuropathy and post-herpetic neuralgia. This surge in demand is prompting pharmaceutical companies to innovate, leading to the introduction of specialized dosage forms and long-acting formulations tailored to meet diverse patient needs. The focus on geriatric patients further emphasizes the industry's commitment to enhancing tolerability and compliance in pain management strategies.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Studies
• Customer Buying Behavior Analysis

Global Pregabalin Market Size by Forms & CAGR (2026-2033)

• Market Overview
• Oral Capsule
• Oral Solution
• Oral Tablet
• Extended Release

Global Pregabalin Market Size by Application & CAGR (2026-2033)

• Market Overview
• Epilepsy
• Neuropathic Pain
• Anxiety Disorder
• Others

Global Pregabalin Market Size by Drug Class & CAGR (2026-2033)

• Market Overview
• Fibromyalgia Agents
• Anticonvulsants
• Others

Global Pregabalin Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Global Pregabalin Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Specialty Clinics
• Homecare
• Others

Global Pregabalin Market Size & CAGR (2026-2033)

• North America (Forms, Application, Drug Class, Distribution Channel, End User)
  • US
  • Canada
• Europe (Forms, Application, Drug Class, Distribution Channel, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Forms, Application, Drug Class, Distribution Channel, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Forms, Application, Drug Class, Distribution Channel, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Forms, Application, Drug Class, Distribution Channel, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Pfizer Inc. (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GSK plc (U.K.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zydus Cadila (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lupin (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amneal Pharmaceuticals LLC. (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla Inc. (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Torrent Pharmaceuticals Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aurobindo Pharma Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Glenmark Pharmaceuticals Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Medley Pharmaceuticals Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Genesisbiotec (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biomax Biotechnics (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations